Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches

Key Takeaways TEM launched xM liquid biopsy to monitor ICI therapy response in solid tumors. Tempus AI introduced Loop, an AI platform combining RWD and CRISPR screens. Development of xH signals TEM's move into WGS to guide hematologic cancer treatment choice.Tempus AI (TEM) continues to push the boundaries of precision medicine through a robust pipeline of research and development (R&D) initiatives. In June, the company introduced xM, a liquid biopsy assay to detect molecular response to immune-checkpoin ...